• MyriadPro Login
  • Register
  • English
  • Français
  • Deutsch
  • Italiano
Myriad Logo
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • News Center
      • Press Releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form
  • Patients
    • Patient Guides
      • EndoPredict
      • MyChoice CDx Plus
      • Prolaris
  • Clinicians
    • Patient Care
      • Assessing prognosis
        • EndoPredict
        • Prolaris
      • Precision medicine
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • BRACAnalysis CDx
      • Predicting disease
        • MyRisk
    • Resources
      • Publications
      • EndoPredict app
      • Order a test -WIP
      • Case studies (new)
      • Clinical trials (new)
  • Pathologists
    • Pathologists & Labs
      • EndoPredict
      • Become a lab partner
    • Test report generators
      • EndoPredict
        • EndoPredict Report Generator 1
        • EndoPredict Report Generator 2
      • Prolaris
        • Prolaris Biopsy Report Generator
  • Our Tests
    • Myriad’s Tests
      • Breast cancer
        • EndoPredict
      • Prostate cancer
        • Prolaris
      • Ovarian cancer
        • MyChoice CDx (Japan)
        • MyChoice CDx Plus (Europe)
        • MyChoice HRD Plus (new)
      • Hereditary cancer testing
        • MyRisk
        • MyRisk Plus (Europe – NEW)
        • BRACAnalysis CDx
      • Carrier scan
        • Foresight
      • Order a test
      • Technical specifications
  • About
    • About Myriad Genetics
      • Myriad History
      • Join the team
    • News
      • News Center
      • Press Releases
      • Events (new?)
      • Media (hold)
        • Articles (hold)
        • Webinars (hold)
        • Podcasts (hold)
    • Locations
      • Find a pathology lab (new)
      • Myriad and distributors
  • Contact Us
    • Offices
      • Corporate Offices
      • International Offices
      • Locations
    • Address
      • Myriad Genetics GmbH
        Leutschenbachstrasse 95
        8050 Zurich, Switzerland
    • Email
      • info@myriadgenetics.eu
    • Contact Form

News Center

News Center
  • Category
    • All
    • Patients
    • Pipeline
    • Products
    • Providers

EndoPredict at SABCS – Prospective long-term and real-world data

December 16, 2022

Two prospective real-world studies presented at SABCS show EndoPredict accurately guides decisions on chemotherapy in ER+, HER2- breast cancer 12th December...

Continue Reading

Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium

September 19, 2022

Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Con...

Continue Reading

EndoPredict informs treatment decisions for premenopausal breast cancer

August 31, 2022

New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid ...

Continue Reading

High adherence to EndoPredict test results in extended endocrine therapy decision making in early breast cancer

June 9, 2022

Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making As a leader in genetic testing and pr...

Continue Reading

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

March 11, 2022

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer BRACAnalysis CDx is now the only ger...

Continue Reading

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan

March 25, 2021

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer...

Continue Reading

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

February 12, 2021

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer Re...

Continue Reading

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

January 8, 2021

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment wi...

Continue Reading

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

November 16, 2020

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genet...

Continue Reading

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

October 16, 2020

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at...

Continue Reading
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Myriad Logo

Health. Illuminated.

  • Contact Us
  • Terms of Use
  • Myriad Genetics, Inc. Privacy Policy
  • Notice of Privacy Practices
  • Cookie Preferences
  • © 2023 Myriad Genetics, Inc.